• Publications
  • Influence
2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology
Developed in Collaboration With the American Association forThoracic Surgery and Society of Thoracic Surgeons, this work aims to provide real-time information about the safe and effective use of ultrasound for diagnosis and treatment of central giant cell granuloma. Expand
Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association.
The American Heart Association commissioned this scientific statement to educate clinicians about CIED infections, provide explicit recommendations for the care of patients with suspected or established CIED infection, and highlight areas of needed research. Expand
ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines
2008;51;2085-2105; originally published online May 15, 2008; J. Am. Coll. Cardiol. Michael O. Sweeney L. Page, Mark H. Schoenfeld, Michael J. Silka, Lynne Warner Stevenson, and Stephen C. Hammill,Expand
Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial.
For patients with standard indications for ICD therapy, no indication for cardiac pacing, and an LVEF of 40% or less, dual-chamber pacing offers no clinical advantage over ventricular backup pacing and may be detrimental by increasing the combined end point of death or hospitalization for heart failure. Expand
ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task
The current update of the ACC/AHA/NASPE Guidelines for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices includes several significant changes in the recommendations and in the supportingExpand
ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities.
The American College of Cardiology Foundation Board of Trustees in February 2008, document be cited as follows. Expand
Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study
An “on-treatment” analysis of the relationship of survival to cardiac rhythm and treatment as they changed over time suggests that any beneficial antiarrhythmic effects of AADs are offset by their adverse effects. Expand
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Sidney C. Smith, Jr, MD, FACC, FAHA, Chair Alice K. Jacobs, MD, FACC, FAHA, Vice-Chair Cynthia D. Adams, RN, PhD, FAHA[§][1] Jeffrey L. Anderson, MD, FACC, FAHA[§][1] Christopher E. Buller, MD,Expand
Left Cardiac Sympathetic Denervation in the Management of High-Risk Patients Affected by the Long-QT Syndrome
LCSD is associated with a significant reduction in the incidence of aborted cardiac arrest and syncope in high-risk LQTS patients when compared with pre-LCSD events, however, LCSD is not entirely effective in preventing cardiac events including sudden cardiac death during long-term follow-up. Expand
Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
In high-risk patients with hypertrophic cardiomyopathy, implantable defibrillators are highly effective in terminating such arrhythmias, indicating that these devices have a role in the primary and secondary prevention of sudden death. Expand